Cargando…
Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance
The increasing use of advanced biologic therapies for patients with severe asthma is transforming the standard of care, clinic workflow, and the clinic business model. Expanded patient access to at-home injection treatment possibilities with some biologics has the potential to improve patient adhere...
Autores principales: | Miyokawa, Reika, Kivler, Celeste, Louie, Samuel, Godor, Dorottya, Tan, Laren, Kenyon, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520541/ https://www.ncbi.nlm.nih.gov/pubmed/33061310 http://dx.doi.org/10.2147/PPA.S227465 |
Ejemplares similares
-
Benralizumab: a unique IL-5 inhibitor for severe asthma
por: Tan, Laren D, et al.
Publicado: (2016) -
LINX(®), a novel treatment for patients with refractory asthma complicated by gastroesophageal reflux disease: a case report
por: Sriratanaviriyakul, Narin, et al.
Publicado: (2016) -
Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022) -
Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016) -
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)